CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 85 enrolled
Drug / intervention
Rituximab +4 moredrug
Likely dose
Rituximab 375 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00504504
NCT00504504Phase 2Completed
CompareCT.gov

A Phase II Study of Rituximab + ABVD for Patients With Hodgkin's Disease

M.D. Anderson Cancer Center·interventional·Posted Jul 20, 2007·Updated Jul 9, 2013

In Brief

A Phase 2 clinical trial evaluating Rituximab, Adriamycin, and 3 other interventions for Lymphoma. Completed, enrolled 85 participants across 1 site.

Detailed Summary

Primary Objective: \- To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy. ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 20, 2007
Enrollment StartMar 1, 2001
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 yearsPosted 18.9 years ago

Interventions

Rituximabdrug

375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.

Adriamycindrug

25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

Bleomycindrug

10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

Vinblastinedrug

6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

Dacarbazine (DTIC)drug

375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.